No definition available.
Hypothalamic dysfunction, including iatrogenic, not elsewhere classified
E4_HYPOTHALDYSF
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
70 |
4. Check minimum number of eventsNone |
70 |
5. Include endpointsNone |
70 |
6. Filter based on genotype QC (FinnGen only) |
67 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Hypothalamic dysfunction, including iatrogenic, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Exclusions for E4_PCOS_BROAD
- Developmental endpoint to exclude non autoimmune-cases from E4_HYTHY_AI_STRICT
- Disorders of other endocrine glands
- Exclusions for E4_PCOS_CONSORTIUM
- Used for control exclusion in common control thyroid runs
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 500 | 262 | 235 |
| Only index persons | 443 | 232 | 211 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 36.55 | 37.24 | 35.34 |
| Only index persons | 34.34 | 35.41 | 33.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 67 | 40 | 27 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 39.32 | 38.41 | 40.68 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 70
- Matched controls
- 700
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H02AB09
ATC
hydrocortisone; systemic
160.1
41.8
41
6
E23.1
ICD-10 Finland
Drug-induced hypopituitarism
+∞
39.3
34
*
E23.3
ICD-10 Finland
Hypothalamic dysfunction, not elsewhere classified
+∞
36.7
32
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
35.4
31
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
24.4
22
*
H03AA01
ATC
levothyroxine sodium; systemic
10.5
22.5
39
75
H01AC01
ATC
somatropin; parenteral
+∞
19.7
18
*
E23.03
ICD-10 Finland
Lack of ACTH
+∞
18.5
17
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
8.8
17.8
31
58
E23.01
ICD-10 Finland
Isolated deficiency of growth hormone
+∞
14.0
13
*
TPH04
NOMESCO Finland
Cathetrisation of vein
5.9
10.9
26
64
102
Kela drug reimbursment
Diabetes insipidus
+∞
10.7
10
*
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
114.9
9.7
10
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
23.7
8.8
12
6
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
+∞
8.5
8
*
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
+∞
8.5
8
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
25.6
8.3
11
5
XF400
NOMESCO Finland
ECG with 12 standard connections
5.6
8.3
19
44
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
13.1
8.2
14
13
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
10.9
8.0
15
17
J01MA12
ATC
levofloxacin; systemic
4.9
7.9
22
60
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
50.9
7.9
9
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
7.3
7.8
19
34
H02AA02
ATC
fludrocortisone; oral
89.1
7.6
8
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
7.4
7
*
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
7.4
7
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
7.1
7.0
17
30
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.0
6.8
26
90
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.4
6.8
18
36
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.7
6.8
37
163
T90
ICPC
Diabetes non-insulin dependent
4.3
6.6
21
63
UGC12
NOMESCO Finland
Flexible bronchoscopy
10.9
6.6
12
13
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
4.3
6.5
21
64
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
4.6
6.4
18
49
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
6.3
6.4
17
34
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
29.6
6.4
8
*
SPAT1203
SPAT
Injection therapy, other than intramuscular or subcutaneous
29.6
6.4
8
*
E23.02
ICD-10 Finland
Neurosecretory dysfunction of the growth hormone
+∞
6.3
6
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
6.3
6
*
E23.0
ICD-10 Finland
Hypopituitarism
+∞
6.3
6
*
R03BB04
ATC
tiotropium bromide; inhalant
8.6
6.3
13
18
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.9
6.2
24
83
WZC30
NOMESCO Finland
Teaching
4.4
6.1
18
51
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
48
193
5.73
11.34
29.2
6.8
1.22
1.21
mmol/l
0.08
43
164
21
44
6.39
10.32
4.5
2.0
15.68
14.18
nmol/l
0.31
21
44
43
196
4.10
7.74
17.5
11.3
1.02
1.18
inr
2.10
14
64
18
43
5.29
7.54
10.1
4.4
104.89
104.16
mmol/l
0.30
18
43
7
0
+∞
7.41
1.1
0.0
—
—
—
0
0
21
67
4.05
6.07
3.2
2.0
—
—
—
0
0
10
11
10.37
5.49
6.4
3.9
24.35
23.24
mmol/l
—
10
11
9
9
11.25
5.19
7.3
3.2
53.44
58.33
%
—
9
9
34
169
2.97
4.73
5.4
3.3
25.97
18.25
ng/l
0.41
27
97
12
24
5.80
4.57
3.2
1.7
—
—
—
0
0
57
390
3.49
4.25
16.5
7.0
79.61
74.52
u/l
0.42
57
363
11
26
4.82
3.69
21.0
7.2
23.70
24.88
mmol/l
0.52
11
26
8
13
6.79
3.61
2.9
1.8
—
—
—
0
0
17
66
3.08
3.53
1.8
1.7
1138.73
1262.52
nmol/l
0.16
11
49
13
39
3.86
3.45
45.6
9.6
2.51
1.93
mmol/l
—
7
29
64
517
3.77
3.17
8.9
4.1
1.57
1.86
mu/l
1.12
59
484
5
5
10.62
3.02
4.0
3.2
—
—
—
0
0
5
5
10.62
3.02
4.0
3.2
—
—
—
0
0
5
5
10.62
3.02
1.2
1.4
—
—
nmol/l
—
0
0
13
47
3.17
3.01
3.3
1.7
—
—
—
0
0
10
28
3.99
2.92
1.5
1.2
—
—
—
0
0
13
48
3.10
2.90
3.5
1.8
—
—
—
0
0
11
34
3.64
2.88
3.0
2.3
65.17
77.89
ml/min/173m2
—
6
18
9
24
4.14
2.78
13.6
11.9
1.87
1.29
%
—
9
24
9
24
4.14
2.78
13.2
11.9
0.68
0.74
%
—
9
24
29
165
2.29
2.77
8.9
2.5
—
—
—
0
0
11
36
3.43
2.71
9.0
3.3
—
—
—
0
0
8
20
4.37
2.66
2.0
5.9
94.00
93.00
%
—
8
20
6
11
5.85
2.60
3.7
2.0
—
—
—
0
0
5
8
6.62
2.41
1.2
2.0
—
—
—
0
0
5
8
6.62
2.41
1.6
1.0
797.40
248.88
pmol/l
—
5
8
5
9
5.88
2.25
6.0
1.2
—
—
—
0
0
6
14
4.58
2.20
2.2
3.1
—
—
—
0
0
28
172
2.05
2.11
2.0
1.7
92.93
94.80
pmol/l
0.07
18
88
64
554
2.81
1.94
51.3
12.0
139.70
139.81
mmol/l
0.17
64
535
65
567
3.05
1.88
42.9
11.0
18.91
20.84
mg/l
0.22
57
413
5
12
4.40
1.85
1.2
1.0
—
—
—
0
0
64
557
2.74
1.78
52.8
12.0
3.90
3.94
mmol/l
0.51
64
538
23
140
1.96
1.73
10.5
3.5
0.00
0.00
estimate
-0.00
11
55
5
129
0.34
1.71
1.4
2.2
—
—
—
0
0
5
14
3.76
1.64
1.4
1.6
—
—
—
0
0
5
121
0.37
1.57
1.4
2.1
—
—
—
0
0
5
15
3.50
1.55
1.4
1.6
—
—
—
0
0
5
15
3.50
1.55
2.2
1.4
—
—
—
0
0
5
15
3.50
1.55
2.6
2.7
—
—
—
0
0
7
28
2.66
1.49
1.0
1.5
—
211.58
miu/ml
—
0
12
5
16
3.28
1.46
3.4
5.9
3.54
3.41
g/l
—
5
16
18
108
1.90
1.39
5.5
2.1
—
—
—
0
0
23
152
1.76
1.31
1.6
1.3
0.44
1.86
u/ml
—
7
39
6
25
2.53
1.27
16.0
4.2
24.77
25.34
mmol/l
—
6
25
5
19
2.75
1.23
1.4
4.2
284.20
167.79
%
—
5
19
30
219
1.65
1.18
8.7
3.0
—
—
—
0
0
36
279
1.60
1.10
8.7
4.2
0.00
0.00
estimate
-0.00
12
54
36
281
1.58
1.05
7.8
3.1
0.00
0.00
estimate
-0.00
12
49
59
520
1.86
1.05
33.0
9.1
86.22
89.87
ml/min/173m2
0.45
48
402
12
69
1.89
1.04
3.9
2.1
0.71
2.94
e6/l
—
7
23
0
30
0.00
1.00
0.0
2.1
—
2.51
—
0
22
13
79
1.79
0.96
3.7
2.1
0.25
0.91
e6/l
—
8
33
35
279
1.51
0.89
8.0
3.0
0.00
0.02
estimate
0.49
12
57
29
232
1.43
0.69
7.1
2.4
—
—
—
0
0
6
39
1.59
0.54
1.7
1.5
—
—
—
0
0
0
15
0.00
0.42
0.0
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
13
106
1.28
0.25
6.0
3.8
32.62
21.99
%
—
5
48
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
14
162
0.83
0.18
1.8
1.7
—
—
—
0
0
44
462
0.87
0.16
4.5
3.5
—
—
—
0
0
9
105
0.84
0.14
1.6
1.6
—
—
—
0
0
7
66
1.07
0.08
4.6
7.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPOTHALDYSF and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_HYPOTHALDYSF.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_HYPOTHALDYSF – Hypothalamic dysfunction, including iatrogenic, not elsewhere classified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data